SCHEMBL25003447

SCHEMBL25003447

CC(=O)C1=CNC(O)c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
PBRM1 Q86U86 2/20 0.36
HSD17B10 Q99714 1/20 0.35
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HDAC9 Q9UKV0 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
KMT2A Q03164 1/20 0.34
AGTR1 P30556 1/20 0.34
CYP1A2 P05177 1/20 0.34
DAPK3 O43293 1/20 0.33
JAK2 O60674 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
PAK4 O96013 1/20 0.33
ABL1 P00519 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30179824 0.67 HSD17B10 (0.51) PBRM1HSD17B10KMT2ACYP1A2GSK3B
SCHEMBL29941489 0.67 HSD17B10 (0.51) PBRM1HSD17B10KMT2ACYP1A2GSK3B
SCHEMBL22397202 0.67 HSD17B10 (0.51) PBRM1HSD17B10KMT2ACYP1A2GSK3B
SCHEMBL4082700 0.67 HSD17B10 (0.51) PBRM1HSD17B10KMT2ACYP1A2GSK3B
SCHEMBL27967876 0.67 EDNRA (0.35) POLBHSD17B10HDAC3HDAC4HDAC7
SCHEMBL26465909 0.63 KDM4E (0.54) POLBHSD17B10KMT2APDK2ALDH1A1
SCHEMBL978600 0.62 KDM4C (0.50) POLBPBRM1KMT2ADAPK3JAK2
SCHEMBL7912897 0.62 EDNRB (0.41) POLBKMT2ACYP1A2ALDH1A1MAPT
SCHEMBL7043488 0.62 HDAC3 (0.57) POLBHSD17B10HDAC3HDAC4HDAC7
Acetone SCHEMBL8469766 0.62 POLB (0.55) POLBHDAC3HDAC4HDAC7HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230045421-A1 SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230045421-A1 SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME HAVCR2, HMBS, AHCY POLB 723/4885PBRM1 337/4885HSD17B10 2301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.